New research indicates that GLP-1 drugs, including popular medications like Ozempic and Wegovy, may be associated with a slight increase in the risk of bone and joint conditions.
The study suggests these medications could potentially raise the risk of osteoporosis, gout, and osteomalacia. Researchers hypothesize that the rapid weight loss facilitated by these drugs may stress the musculoskeletal system, and that accelerated weight reduction can also trigger uric acid spikes linked to gout. Reduced food and nutrient intake might also play a role.
Previous findings have already linked GLP-1 medications to disruptions in calcium production, essential for bone health. While these drugs offer significant health benefits beyond weight management and diabetes control, their relative newness means long-term effects are still being fully understood.
Lead author Muaaz Wajahath, a medical student at Michigan State University, noted that five- and 10-year follow-up data for patients on GLP-1 medications is now becoming available.
A five-year analysis of health records for over 73,000 individuals taking GLP-1 medications revealed a 0.9% higher risk of osteoporosis, a 0.8% higher risk of gout, and a 0.1% higher risk of osteomalacia compared to a control group. The study acknowledges it does not prove direct causation, as factors like diet and exercise habits were not fully accounted for.
Clinicians are advised to consider bone health surveillance for patients prone to these conditions, especially those on GLP-1 medications. This approach could help prevent potential delayed-onset complications.
Conflicting findings also exist, with some research indicating GLP-1 users may have better recovery outcomes from orthopedic procedures. The overall risk-benefit balance of GLP-1 receptor agonists is still under scrutiny, with other potential risks including vision loss and pancreas issues also being investigated.